HORSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX:LCP) (the “Company” or “LCP”), an emerging specialty pharmaceutical company, today announced that it has initiated a Phase II clinical trial of LCP-Tacro for the treatment of autoimmune hepatitis (“AIH”), also referred to as chronic active hepatitis, a disease which causes a person’s body to reject its own liver. The clinical trial is expected to enroll up to 60 patients in up to 12 centers throughout the US and Canada. The Company expects to report top-line clinical trial results in the first half of 2009 (1H09).
